^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CFI-402411

    i
    Other names: CFI-402411, CFI402411, CFI 402411
    Associations

    News

    Trials
    Company:
    Treadwell Therap
    Drug class:
    HPK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    TWT-101: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Treadwell Therapeutics, Inc | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • CFI-402411
    over1year
    TWT-101: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Treadwell Therapeutics, Inc | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Nov 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • CFI-402411
    almost4years
    TWT-101: Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Treadwell Therapeutics, Inc | Trial primary completion date: Dec 2021 --> Dec 2023
    Trial primary completion date • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • CFI-402411
    5years
    Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Treadwell Therapeutics, Inc | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • PD(L)-1 Biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • CFI-402411
    over5years
    Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=170, Not yet recruiting, Treadwell Therapeutics, Inc
    Clinical • New P1/2 trial • Combination therapy • PD(L)-1 Biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • CFI-402411